The single biggest factor
However, severe abdominal pain, persistent vomiting, inability to keep food or water down, or signs of acute pancreatitis (upper left pain radiating to the back) require immediate emergency evaluation
Semaglutide and Tirzepatide is FDA-approved and is an injection that suppresses the appetite and assists in weight loss management
Injectable tirzepatide shows: ~1521% average weight loss up to ~26% with lifestyle changes consistent long-term outcomes Oral GLP-1 drugs, like Rybelsus, typically show: lower weight loss at standard doses need for higher dosing to match injections stricter intake conditions If oral tirzepatide eventually becomes available, it will likely require higher doses, produce slower or less pronounced weight loss and come with stricter intake instructions
If a dose is missed, it should be taken as soon as remembered, with certain guidelines depending on the specific medication
Access to NHS weight loss injections depends on NICE criteria, local service design and phased implementation
